BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular ...
Tech Times on MSN
PMN310 cuts Alzheimer oligomers in humans, dodging side effects that limit rival drugs
Amyloid oligomers — not plaques — may be the true neurotoxic driver of Alzheimer's disease, and ProMIS Neurosciences now has ...
Scientists have kept donated human retinas responsive to light for up to 10 hours after death, marking a significant advance ...
If that growth materializes, there's enough upside for Circle stock to double within the next four years.
Dr. J. Mikhail Kellawan received his BSc (Honors) from the University of Guelph (Guelph, Ontario, Canada) and his MSc from the University of Victoria (Victoria, British Columbia, Canada). He completed ...
Doxorubicin cardiomyopathy (DoxCM) remains a significant clinical problem, but its underlying mechanisms remain incompletely understood. Identifying DoxCM mechanisms can lead to therapeutic ...
While humans evolved to perform routine endurance activity, recent secular trends in the United States and globally have resulted in a dramatic rise in the amount of time spent inactive in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results